ADAPTIVE BIOTECHNOLOGIES CORPORATION Fair Value Adjustment of Warrants
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Fair Value Adjustment of Warrants of $2.27 million for the 12-month period ending 2019-12-31, per its 10-K filed 2022-02-15.
Discontinued › Cash Flow
us-gaap:FairValueAdjustmentOfWarrants · last filed 2022-02-15
- ADAPTIVE BIOTECHNOLOGIES CORPORATION fair value adjustment of warrants for the quarter ending 2019-12-31 was $0.00.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION fair value adjustment of warrants for the quarter ending 2019-09-30 was $0.00.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION fair value adjustment of warrants for the quarter ending 2019-06-30 was $2.25M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION fair value adjustment of warrants for the quarter ending 2019-03-31 was $18.00K.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION fair value adjustment of warrants for fiscal 2019 was $2.27M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION fair value adjustment of warrants for fiscal 2018 was -$6.00K.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION fair value adjustment of warrants for fiscal 2017 was -$23.00K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $0.00 derived: sum of 2 quarters · filed 2022-02-15 | $2.25M derived: sum of 3 quarters · filed 2022-02-15 | $2.27M 10-K · filed 2022-02-15 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $2.25M derived: sum of 2 quarters · filed 2020-11-10 | $2.27M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $2.27M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $18.00K 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | -$6.00K 10-K · filed 2021-02-24 | |||
| 2017-12-31 | -$23.00K 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |